[1]李晨阳,张学红.人参皂苷Rg3通过PI3K/Akt信号通路抑制大鼠卵巢型子宫内膜异位症血管生成相关因子表达机制研究[J].西部中医药,2022,35(11):66-72.[doi:10.12174/j.issn.2096-9600.2022.11.12]
　LI Chenyang,ZHANG Xuehong.Study on the Mechanism of Inhibiting Angiogenesis-related Factors Expression in Ovarian Endometriosis Rats by Ginsenoside Rg3 via P13K/Akt Signaling Pathway[J].Western Journal of Traditional Chinese Medicine,2022,35(11):66-72.[doi:10.12174/j.issn.2096-9600.2022.11.12]
点击复制

人参皂苷Rg3通过PI3K/Akt信号通路抑制大鼠卵巢型子宫内膜异位症血管生成相关因子表达机制研究
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年11期
页码:
66-72
栏目:
出版日期:
2022-11-15

文章信息/Info

Title:
Study on the Mechanism of Inhibiting Angiogenesis-related Factors Expression in Ovarian Endometriosis Rats by Ginsenoside Rg3 via P13K/Akt Signaling Pathway
作者:
李晨阳, 张学红
兰州大学第一临床医学院，甘肃 兰州 730000
Author(s):
LI Chenyang, ZHANG Xuehong
First Clinical Medical College, Lanzhou University, Lanzhou 730000, China
关键词:
子宫内膜异位症; 卵巢型; PI3K/Akt信号通路; 血管生成相关因子; 人参皂苷Rg
Keywords:
ovarian endometriosis; P13K/Akt signaling pathway; angiogenesis-related factors; ginsenoside Rg
分类号:
R271.19
DOI:
10.12174/j.issn.2096-9600.2022.11.12
文献标志码:
A
摘要:
目的探讨人参皂苷Rg3抑制卵巢型子宫内膜异位症（ovarian endometriosis，OEMs）大鼠血管生成相关因子表达及其机制。 方法采用异位移植的方法建造大鼠OEMs模型，给予人参皂苷Rg3干预治疗，检测大鼠体质量；干预后采集大鼠卵巢型异位子宫，记录其体积和质量，利用定量聚合酶链反应（quantitative polymerase chain reaction，qPCR）法检测子宫血管内皮生长因子（vascular endothelial growth factor,VEGF）mRNA、血管内皮细胞生长因子受体2（vascular endothelial growth factor receptor 2,VEGFR-2）mRNA、缺氧诱导因子1α多肽（hypoxia-inducible factor 1-alpha,HIF-1α）mRNA、基质金属蛋白酶-9（matrix metalloproteinase-9，MMP-9）mRNA、基质金属蛋白酶-2（matrix metalloproteinase-2，MMP-2）mRNA的表达，蛋白印记Western blot和免疫组化法检测子宫磷脂酰肌醇-3-羟激酶（phosphatidylinositol 3-hydroxykinase, PI3K）、磷酸化磷脂酰肌醇-3-羟激酶（phosphorylated phosphatidylinositol 3-hydroxykinase，p-PI3K）、丝氨酸/苏氨酸蛋白激酶（serine/threonine protein kinase，Akt1）、磷酸化丝氨酸/苏氨酸蛋白激酶（serine/threonine protein kinase，p-Akt1）、细胞外调节蛋白激酶（extracellular regulated protein kinases，ERK1/2）、磷酸化细胞外调节蛋白激酶（phosphorylated extracellular regulated protein kinases，p-ERK1/2）蛋白。 结果人参皂苷Rg3可浓度依赖性减缓子宫异位大鼠体质量下降幅度，降低异位子宫质量和体积，降低异位子宫组织中血管生成相关因子VEGF、VEGFR-2、HIF-1α、MMP-9、MMP-2的mRNA表达及蛋白表达和p-PI3K、p-Akt1、p-ERK1/2蛋白表达，对PI3K、Akt 1、ERK1/2总蛋白无影响。 结论人参皂苷Rg3可抑制OEMs PI3K/Akt通路的激活，降低血管生成相关因子表达和ERK1/ERK2磷酸化水平，抑制OEMs血管生成。
Abstract:
ObjectiveTo discuss the inhibitory effects of ginsenoside Rg3 on the expressions of angiogenesis-related factors in ovarian endometriosis（OEMs） rats and its mechanism. MethodsHeterotopic transplantation was adopted to establish rat model with OEMs, and the models were intervened and treated with ginsenoside Rg3, to detect body mass of the rats; after the intervention, ovarian type ectopic uterus of the rats were collected to record the volume and mass, qPCR was used to determine the expressions of VEGF mRNA, VEGFR-2 mRNA, HIF-1α mRNA, MMP-9 mRNA and MMP-2 mRNA of the uterus, Western blot and immunohistochemical method were applied to measure P13K, p-P13K, Akt1, p-Akt1, ERK1/2, p-ERK1/2 protein in the womb. ResultsGinsenoside Rg3 could slow down the decrease of body mass of the rat model in a dose-dependent manner, reduce the mass and volume of ectopic uterus, lower the expressions of angiogenesis-related factors VEGF-2 mRNA, VEGFR mRNA, HIF-1α mRNA, MMP-9 mRNA and MMP-2 mRNA, and the contents of p-P13K, p-Akt1, p-ERK1/2 protein of the uterus, while it shows no influence on total protein of P13K, Akt1 and ERK1/2. ConclusionRg3 could inhibit the activation of P13K/Akt signaling pathway in OEMs rats, lower the expressions of angiogenesis-related factors and ERK1/ERK2 phosphorylation level, and refrain angiogenesis in OEMs.

相似文献/References:

[1]王颖.辨证论治子宫内膜异位症118例[J].西部中医药,2013,26(12):85.
　WANG Ying.Syndrome Differentiation and Treatment for 118 Cases of Endometriosis[J].Western Journal of Traditional Chinese Medicine,2013,26(11):85.
[2]葛慧娟,曹保利.子宫内膜异位症术后应用复方莪术散的疗效观察[J].西部中医药,2014,27(04):100.
　GE Huijuan,CAO Baoli.Clinical Observation on Compound EZhu Powder Applied to the Patients after the Surgery of Endometriosis[J].Western Journal of Traditional Chinese Medicine,2014,27(11):100.
[3]李红霞,万国蕊,徐静,等.三花益肾汤治疗子宫内膜异位症临床观察[J].西部中医药,2015,28(01):7.
[4]陆建英,董莉,谭蕾,等.朱南孙治疗子宫内膜异位症经验举隅*[J].西部中医药,2013,26(10):42.
　LU Jianying,DONG Li,TAN Lei,et al.Examples of Zhu Nansun Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2013,26(11):42.
[5]董迹菲,翟培杞,孙炜,等.基于数据挖掘的针灸治疗子宫内膜异位症选穴配伍规律的文献研究[J].西部中医药,2015,28(06):86.[doi:2015/6/16 0:00:00]
[6]胡淑寒,曹保利△,刘霞,等.中药治疗子宫内膜异位症的用药规律研究[J].西部中医药,2018,31(09):87.
　HU Shuhan,CAO Baoli,LIU Xia,et al.Drug Use Law of Traditional Chinese Medicine in Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2018,31(11):87.
[7]唐晓琳,石璇△.中药治疗子宫内膜异位症的临床效果[J].西部中医药,2017,30(01):66.
　TANG Xiaolin,SHI Xuan.Clinical Effects of Chinese Materia Medica in Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2017,30(11):66.
[8]刘帅,曹保利.莪术油对大鼠子宫内膜异位症基质细胞衍生因子-1及其受体表达的影响[J].西部中医药,2018,31(03):26.
　LIU Shuai,CAO Baoli.The Effects of Curcuma Zedoary Oil on the Expressions of Stromal Cell Derived Factor-1 and Its Receptor in Endometriosis Rats Model[J].Western Journal of Traditional Chinese Medicine,2018,31(11):26.
[9]徐群群,卢敏,曹阳,等.清热化瘀法对子宫内膜异位症患者血管生成机制的影响[J].西部中医药,2019,32(02):1.
　XU Qunqun,LU Min,CAO Yang,et al.The Effects of Heat-clearing Stasis-eliminating Method on the Mechanism of Angiogenesis of Endometriosis Patients[J].Western Journal of Traditional Chinese Medicine,2019,32(11):1.
[10]张彩凤.益肾汤联合孕三烯酮治疗子宫内膜异位症[J].西部中医药,2019,32(03):87.
　ZHANG Caifeng.Kidney-nourishing Decoction Combined with Gestrinone in Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2019,32(11):87.
[11]葛静,滑芳,冯艳萍.红藤方加减治疗卵巢型子宫内膜异位症74例临床观察[J].西部中医药,2020,33(04):34.[doi:10.12174/j.issn.1004-6852.2020.04.11]
　GE Jing,HUA Fang,FENG Yanping.Clinical Observation on Modified Hongteng Prescription in the Treatment of 74 Cases of Ovarian Endometriosis[J].Western Journal of Traditional Chinese Medicine,2020,33(11):34.[doi:10.12174/j.issn.1004-6852.2020.04.11]

备注/Memo

备注/Memo:
李晨阳（1987—），女，硕士学位，医师。研究方向：妇产科。甘肃省自然科学基金（18JR3RA350/092NKDA009）。
更新日期/Last Update: 2022-11-15